Clinical trials

Completed

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation

REP0104

What is the purpose of this study?

The objective of this clinical trial was to explore the safety and efficacy of repertaxin in preventing the primary graft dysfunction (PGD) after lung transplantation.

Trial overview

Condition

Ischemia-Reperfusion Injury in Lung Transplantation

Study Identifiers

NCT00224406

Study type

Interventional

Intervention

Drug: Repertaxin

Phase

II

Start date

May 2005

End Date

May2008

Enrollment Goal

100 patients

Going deep into the trial

Eligibility/Recruitment

Age

 
18
 
65

Gender

Accepts healthy volunteers

Key Criteria

close

Inclusion

close

Exclusion

Desired Outcomes

close

Primary Outcomes

close

Secondary Outcomes

Find your nearest centre:

Loading...

loading...